In addition, the FDA designated the investigation of selatogrel for the treatment of suspected AMI as a "fast-track" development program. This designation is intended to promote communication and collaboration between the FDA and pharmaceutical companies for drugs that treat serious conditions and fill an unmet medical need. About cenerimod Cenerimod, the result of 20 years of research in Idorsia's labs, is a highly selective S1P 1 receptor modulator, given as an oral once-daily tablet.